Google
CMMB 株価分析 — CHEMOMAB THERAPEUTICS LTD DRC (Healthcare >> Biotechnology)
CMMB に関するよくある質問
CMMBのROE（自己資本利益率）は？
CHEMOMAB THERAPEUTICS LTD DRCのROEは-69.72%です。
CMMBの配当利回りは？
CHEMOMAB THERAPEUTICS LTD DRCの配当利回りは0.00%です。
CMMBの品質スコア（Quality Score）は？
当社のAIはCMMBの総合財務品質を100点中38点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
CMMBは今が買い時ですか？
当社AIのタイミングスコアは100点中27点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
CMMBはどのセクターに属しますか？
CHEMOMAB THERAPEUTICS LTD DRCはHealthcare >> Biotechnologyセクターに分類されます（NASDAQ市場）
CMMB AI Analysis Summary
Our AI summary for CMMB: CHEMOMAB THERAPEUTICS LTD DRC (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -69.72%, a dividend yield of 0.00%. Its financial Quality Score stands at 38/100 — fundamentals below the market average. The AI Timing Score is 27/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 1.55
Price
0.02
(1.31%)
Day Change
|
|
|---|
CMMB, ファンダメンタルスコアはnot good ( ファンダメンタル = 38) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
ROEの伸びが低い
平均ROEが低い
ROAがROEに比べて低い
ROAの伸びが低い
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
48% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 98 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 1.55 |
| PBV / Sector |
1.05 / 5.20
GREAT
|
| Earning Per Share | -1.03 |
| PE / Sector |
N/A / 19.97
|
| PEG or PE/Growth / Sector |
N/A / 1.22
|
| Average 1M Daily Value |
0.44 M
GREAT
|
| Average 1W Daily Value |
0.10 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
45% |
| ポイントになる統計 |
|
37% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-01 07:59:39 |
| Symbol | CMMB |
| Name | CHEMOMAB THERAPEUTICS LTD DRC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 7.33 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 11.21 / 9,903.94 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: Building C, Tel Aviv-Yafo, Israel, 6158101
Phone: 972 77 331 0156
Website: https://www.chemomab.com
Sector: Healthcare >> Biotechnology
Description: Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat systemic sclerosis. The company was founded in 2011 and is based in Tel Aviv-Yafo, Israel.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
